Document 2846
 DOCN  M94A2846
 TI    Antiviral combined and thymostimulin in patients with HIV stages III and
       IV. Effects on the CD4 cells counts.
 DT    9412
 AU    Conde-Mercado JM; Feregrino Goyos M; Eid Lidt G; Torras GV; Gallegos
       Perez H; Alvarado Diez D; Clinica isi de Norteamerica, Mexico D.F.
       Mexico.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):211 (abstract no. PB0273). Unique
       Identifier : AIDSLINE ICA10/94369729
 AB    OBJECTIVES: We tried to evaluate the immunomodulating effects of the TP1
       ((Thymostimulin derived from calf thymus) in HIV patients with less than
       300 CD4 cells, associating the combination of AZT + DDC or AZT + DDC +
       NAC. METHODS: We studied 15 patients. They received 50 mg IM daily of
       thymostimulin over a period of 120 days. All the patients received 500
       mg of AZT and 2.25 mg of DDC and 5 of them 1500 mg of N-acetylcysteine
       orally simultaneously. We compared results with a control group of 100
       patients who received only AZT + DDC. and formed the Group II. The group
       I with thymostimulin was formed by 15 patients, 5 with more than 100 CD4
       (average 151), and 10 with less of 100 CD4 cells.. All the patients had
       a counts of total lymphocytes, CD4, CD8 and antigen p 24 on a monthly
       basis. RESULTS: Patients of the control group (Group II) had a gradual
       increases of CD4 of 12, 24 and 35% above basal number with an average of
       170 CD4 on day 0. The number of lymphocytes, and CD8 has slightly
       increase, and p24 antigens did not modify significantly. In the Group
       IA, we observed increases of CD4 from a basal average of 152 to 175, 225
       and 285 with increases of 80%. (p < 0.05). In the group IB with less
       than 100 CD4 basal count with average of 54 they had increase less
       significantly than group IA, without modification in 2 patients with
       less than 20 CD4. In the others 8 patients the increase was 54, 66, 77
       and 85 CD4 cells (+57%). Lymphocytes CD8 and total increase in average
       of 75% in both groups. We did not observe modification in the p 24
       antigen level. CONCLUSIONS: Thymostimulin can improve results of
       combined antiviral therapy with AZT + DDC in patients with more than 20
       CD4. The responses is more significantly in patients with more than 100
       CD4.
 DE    Acetylcysteine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/  THERAPEUTIC USE
       Acquired Immunodeficiency Syndrome/DRUG THERAPY/THERAPY  Adjuvants,
       Immunologic/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/  *THERAPEUTIC USE
       Antiviral Agents/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/  *THERAPEUTIC
       USE  Biological Response Modifiers/ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS/*THERAPEUTIC USE  Combined Modality Therapy  Comparative Study
       Drug Therapy, Combination  Human  HIV Core Protein p24/BLOOD  HIV
       Infections/DRUG THERAPY/*THERAPY  Interferon Inducers/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/  *THERAPEUTIC USE  Leukocyte Count/*DRUG EFFECTS
       Thymus Extracts/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/  *THERAPEUTIC
       USE  Treatment Outcome  *T4 Lymphocytes  Zalcitabine/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/THERAPEUTIC  USE  Zidovudine/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/THERAPEUTIC  USE  CLINICAL TRIAL  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).